Table 4.
Clinicopathological and immunohistochemical characteristics and their relationship with achieving pathological complete response in the breast and axilla.
| Characteristic | Neoadjuvant Group (N = 118) | pCR Breast (N = 55) | RD Breast (N = 63) | pCR Axilla (N = 79) | RD Axilla (N = 39) | P-value | |
|---|---|---|---|---|---|---|---|
| Age at diagnosis | Mean ± SD (range); median | 51.5 ± 12.0, (23–79); 51 | 50.7 ± 12.3 (23–77), 50 | 52.1 ± 11.8 (23–79), 51 | 50.2 ± 11.7 (23–79), 50 | 53.4 ± 13.4 (23–79), 51 | 0.205 □ |
| Symptomatic | N (%) | 100 (84.7%) | 48 (87.3%) | 52 (82.5%) | 67 (84.8%) | 33 (84.6%) | 0.612, 0.573 |
| Screening | 18 (15.2%) | 7 (12.7%) | 11 (17.5%) | 12 (15.2%) | 6 (15.4%) | (Both ¶) | |
| Grade 1 | N (%) | 1 (0.8%) | 0 (0.0%) | 1 (1.6%) | 1 (1.3%) | 0 (0.0%) | 0.709, 0.064(Both χ2) |
| Grade 2 | 52 (44.1%) | 24 (43.6%) | 28 (44.4%) | 29 (36.7%) | 23 (59.0%) | ||
| Grade 3 | 62 (52.6%) | 29 (52.7%) | 33 (52.4%) | 48 (60.7%) | 14 (35.9%) | ||
| Unknown | 3 (2.5%) | 2 (3.6%) | 1 (1.6%) | 1 (1.3%) | 2 (5.1%) | ||
| IDC | N (%) | 93 (78.8%) | 41 (74.6%) | 52 (82.5%) | 68 (86.1%) | 25 (64.1%) | 0.226, 0.099(Both χ2) |
| ILC | 4 (3.4%) | 1 (1.8%) | 3 (4.8%) | 1 (1.3%) | 3 (7.7%) | ||
| Mixed | 2 (1.7%) | 1 (1.8%) | 1 (1.6%) | 1 (1.3%) | 1 (2.6%) | ||
| Other | 2 (1.7%) | 0 (0.0%) | 2 (3.2%) | 2 (2.6%) | 0 (0.0%) | ||
| IBC | 14 (11.9%) | 10 (18.2%) | 4 (6.4%) | 5 (6.3%) | 9 (23.1%) | ||
| Unknown | 3 (2.5%) | 2 (3.6%) | 1 (1.6%) | 2 (2.6%) | 1 (2.6%) | ||
| T1 | N (%) | 11 (9.3) | 5 (9.1%) | 6 (9.5%) | 10 (12.7%) | 1 (2.6%) | 0.031∗, 0.078 (Both χ2) |
| T2 | 55 (46.6%) | 20 (36.4%) | 35 (55.6%) | 37 (46.8%) | 18 (46.2%) | ||
| T3 | 17 (14.4%) | 6 (10.9%) | 11 (17.5%) | 10 (12.7%) | 7 (18.0%) | ||
| T4 | 17 (14.4%) | 11 (20.0%) | 6 (9.5%) | 7 (8.9%) | 10 (25.6%) | ||
| TX | 18 (15.3%) | 13 (23.6%) | 5 (7.9%) | 15 (19.0%) | 3 (7.7%) | ||
| N0 | N (%) | 20 (17.9%) | 8 (14.6%) | 12 (19.1%) | 20 (25.3%) | 0 (0.0%) | 0.328, <0.001∗ (Both χ2) |
| N1 | 59 (49.2%) | 30 (54.5%) | 29 (46.0%) | 32 (40.5%) | 27 (69.2%) | ||
| N2 | 13 (11.0%) | 4 (7.3%) | 9 (14.3%) | 4 (5.1%) | 9 (23.1%) | ||
| N3 | 3 (2.5%) | 0 (0.0%) | 3 (4.8%) | 0 (0.0%) | 3 (7.7%) | ||
| NX | 23 (20.4%) | 13 (23.6%) | 10 (15.9%) | 23 (29.1%) | 0 (0.0%) | ||
| ER positive | N (%) | 66 (55.9%) | 23 (41.8%) | 43 (68.3%) | 41 (51.9%) | 25 (64.1%) | 0.009∗, 0.362 (Both ¶) |
| ER negative | 52 (44.1%) | 32 (58.2%) | 20 (31.7%) | 38 (48.1%) | 14 (35.9%) | ||
| PgR positive | N (%) | 56 (47.6%) | 18 (32.7%) | 38 (60.3%) | 37 (46.8%) | 19 (48.7%) | 0.006∗, 0.547 (Both ¶) |
| PgR negative | 62 (52.4%) | 37 (67.3%) | 25 (39.7%) | 42 (53.2%) | 20 (51.3%) | ||
| LBBC | N (%) | 70 (59.3%) | 29 (52.7%) | 41 (65.1%) | 46 (58.2%) | 24 (61.5%) | 0.009∗, 0.248 (Both ¶) |
| HER2 enriched | 48 (40.7%) | 26 (47.3%) | 22 (34.9%) | 33 (41.8%) | 15 (38.5%) |
N; number, SD; standard deviation, pCR; pathological complete response, RD; residual disease, IDC; invasive ductal carcinoma, ILC; invasive lobular carcinoma, mixed; mixed histopathological subtype, IBC; inflammatory breast cancer, T1; tumour stage 1, N1; nodal stage 1, SLNB; sentinel lymph node biopsy, ALND; axillary lymph node dissection, ER; estrogen receptor, PgR; progesterone receptor, LBBC; luminal b breast cancer, HER2; human epidermal growth factor receptor-2.
□ denotes one-way analysis of variance (ANOVA) test.
¶ denotes Fisher's exact test.
χ2 denotes Chi-square test.